Since its inception, the study of apoptosis has been intricately linked to the field of cancer.
The term apoptosis was coined more than five decades ago following its identification in …

Simple Summary The treatment of chronic lymphocytic leukemia (CLL) has dramatically
changed following the availability of new drugs with targeted mechanisms of action …

Chromosomal abnormalities are frequent in chronic lymphocytic leukemia (CLL), and most
have prognostic value. In addition to the four well-known abnormalities (13q, 11q and 17p …

Venetoclax, a BH3 mimetic, is a novel targeted anti-cancer drug with a unique mechanism of
action leading to the execution of apoptosis through inhibition of the Bcl-2 protein. The …

Clonal expansion of B-cells, from the early stages of monoclonal B-cell lymphocytosis
through to chronic lymphocytic leukemia (CLL), and then in some cases to Richter's …

Overexpression of the anti-apoptotic protein BCL-2 is a key factor in the pathogenesis of
chronic lymphocytic leukemia (CLL) and is associated with poor clinical outcomes …

Recent progress in the use of massive sequencing technologies has greatly enhanced our
understanding of acute myeloid leukemia (AML) pathology. This knowledge has in turn …

Patients with chronic lymphocytic leukemia (CLL) exhibit diverse clinical outcomes. An
expanding array of genetic tests is now employed to facilitate the identification of patients …

To our knowledge, venetoclax is the first example of personalized medicine for multiple
myeloma (MM), with meaningful clinical activity as a monotherapy and in combination in …

Simple Summary The therapeutic landscape of Chronic Lymphocytic Leukemia (CLL) has
dramatically changed in recent years, with a shift from chemoimmunotherapy towards many …